CANNAHealthcare Magazine June / July 2017 | Page 27

In The LAB

Pioneering Cannabis Clinical Trials

by Christina DiArcangelo Puller, CEO and Founder of Affinity Bio Partners

Through the many years of clinical research and drug development, within the industry we have seen drugs, devices and biologics approved by the FDA. The reason that the biotechs and pharmaceutical companies have received these approvals is because of their ability to successfully plan, safely manage and execute effective clinical trials.

As we embark upon this new frontier of natraceutical, the same principals for running clinical trials with Cannabis should be applied as clinical trials and studies play a critical role in the development of new and novel therapies. The primary focus of Cannabis Clinical Trials should always be to ensure that the study is being run in a safe manner. Additionally, another point to consider is that Cannabis Clinical Trials are effective to the therapeutic indication that is being treated.

As the CEO of Affinity Bio Partners, the premier Cannabis Clinical Research Organization, the wealth of knowledge that has been established in clinical research field should likewise be applied to Cannabis Clinical Trials. This is a primary focus for our organization to ensure that this ground-breaking nutraceutical serves it’s intended purpose. Further, the safety and ethical treatment of each patient in Cannabis Clinical trials is a primary focus.

With great humility, Affinity Bio Partners embraces the opportunity we have been presented with being the pioneer in this novel, innovative and ground-breaking form of treatment. While this form of treatment is in it’s infancy, we at Affinity Bio Partners are extremely excited about the possibilities that lay ahead with Cannabis in clinical trials.

The Premier Cannabis CRO

pioneering the way for the future

use of cannabis in clinical research

27